[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590314":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":13,"interventions":13,"overallOfficials":13,"centralContacts":18,"locations":24,"responsibleParty":39,"collaborators":13,"id":43,"slug":13,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":13,"enrollmentInfo":52,"targetDuration":13,"studyType":55,"phases":13,"briefSummary":56,"conditions":57,"keywords":13,"overallStatus":27,"whyStopped":13,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Patient Satisfaction (using a 5-point likert scale)","Glucose Monitoring Satisfaction Survey","15 days",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","• Admitted patient with Type 1 or Type 2 diabetes.",[19],{"name":20,"role":21,"phone":22,"phoneExt":13,"email":23},"Mathew P Monterola, Doctor of Nursing Practice","CONTACT","3109677434","Mathew.Monterola@cshs.org",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":13},"Cedars-Sina Medical Center","RECRUITING","Los Angeles","California","90048","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-118.24368,34.05223,{"lat":37,"lon":36},{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Matthew Monterola","Associate Director, Clinical Support Programs","100590314",false,"NCT06965803","This Study is to Evaluate Whether Receiving Education and Glucose Monitoring With the CGM Device Will Improve Patient-reported Outcomes by Improving Patient's Satisfaction and Quality of Life (QOL) With Glucose Monitoring Device","Continuous Glucose Monitor (CGM) Discharge Program","CGM QOL","Inclusion Criteria:\n\n* aged 18 or older\n* diagnosed with Type 1 or Type 2 Diabetes who are on insulin\n* able to speak and understand English language\n* scheduled to receive a standard inpatient diabetes education consultation\n* must not have used CGM in the six months prior to admission\n* owns a smartphone\n* demonstrates the ability to follow instructions and be capable of providing informed consent to participate in the program\n\nExclusion Criteria:\n\n* those who are known to be pregnant. This is due to complexity of pregnancy-related changes in glucose metabolism and increased skin sensitivity, or changes in skin condition to adhesives and materials used in CGM devices.\n* non-English speakers. As this is small study to evaluate which method is favorable using a survey only validated in English, enrolling non-English speakers would require additional resources\u002Ftranslations\u002Fpersonnel for evaluation and the education intervention that are not logistically possible right now.","ALL","18 Years",{"count":53,"type":54},37,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to improve patient-reported outcomes by improving patient's satisfaction and quality of life (QOL) with glucose monitoring device through pre and post satisfaction survey of patient with diabetes.",[58],"Diabetes Mellitus","2026-03-16",{"date":61,"type":62},"2026-03-18","ACTUAL",{"date":64,"type":62},"2025-10-01",{"date":66,"type":54},"2026-12-30",{"name":5,"class":6},1]